Sovateltide
Sovateltide is a synthetic analog of endothelin-1 that works as a selective endothelin-B receptor agonist. In May 2023, it was approved in India to treat acute ischemic stroke. The drug was developed by Pharmazz. Sovateltide stimulates neural progenitor cells in the brain and promotes neurovascular remodeling by forming new neurons and blood vessels. Sovateltide also protects neural mitochondria and enhances their biogenesis.